Daniela Salvemini, Ph.D.
In a recent paper published in the journal Pain, Saint Louis University researchers describe their success in an animal model in turning off the excruciating pain that often accompanies a colorectal cancer drug.
Daniela Salvemini, Ph.D., professor of pharmacology and physiology at SLU, studies pain pathways, the series of interactions between molecular-level components that lead to pain in the body.
One type of pain she examines is chemotherapy induced neuropathic pain (CINP), a debilitating side effect of chemotherapy that can appear as tingling or numbness in the hands and feet, shooting or burning pain in the limbs, or can feel like hot or cold temperature extremes. In addition to causing patients suffering, CINP is often a limiting factor when it comes to treatment.
“Thanks to the increased efficacy of cancer treatment, there are nearly 14 million cancer survivors in the United States,” Salvemini said. “Many of these survivors suffer from long-term side effects of CINP, for which there are no proven strategies for prevention or treatment.
“This is a huge unmet medical need.”
In her current paper, Salvemini studied the platinum-based chemotherapy drug oxaliplatin which is widely used to treat colorectal cancer. Over 60 percent of patients who received oxaliplatin develop CINP, and it can last for years after treatment.
The research team found that the pain pathway associated with this drug was driven by increased expression of an enzyme, adenosine kinase, in astrocytes (a type of central nervous system cell) and decreased adenosine signaling at a key receptor, A3AR. By supplementing this signaling with A3AR agonists, the researchers were able to block the development of CINP without interfering with the anticancer properties of platinum based drugs.
These findings advance researchers’ understanding of pain pathways and provide new information about how drugs may be able to treat chemotherapy pain. Perhaps most encouraging, existing A3AR agonists currently are being studied in advanced clinical trials as novel anticancer agents. This paper makes a strong case for evaluating those drugs for use together with oxaliplatin to limit CINP while treating cancer.
Learn more: In Laboratory, SLU Scientist Turns Off Chemo Pain
The Latest on: Neuropathic pain
via Google News
The Latest on: Neuropathic pain
- How Pain Management Specialists Can Help You Treat Chronic Painon February 23, 2021 at 8:23 am
Here's what causes chronic pain and how pain specialists use medications and treatments to help manage symptoms. The post How Pain Management Specialists Can Help You Treat Chronic Pain appeared first ...
- These 3 antibiotics could offer alternative to addictive opioid pain relieverson February 23, 2021 at 3:17 am
In a new study, researchers found that three decades-old antibiotics administered together can block a type of pain triggered by nerve damage. These drugs—demeclocycline, chlortetracycline, and ...
- OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammationon February 22, 2021 at 11:00 pm
OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs ...
- Three longtime antibiotics could offer alternative to addictive opioid pain relieverson February 22, 2021 at 2:27 pm
Three decades-old antibiotics administered together can block a type of pain triggered by nerve damage in an animal model, UT Southwestern researchers report. The finding, published online today in ...
- Neuropathic Pain Management Market 2021 : Top countries Data, Market Size, In-Depth Analysis with Booming Trends and Segmentation Forecast to 2026on February 22, 2021 at 5:34 am
Feb 22, 2021 (The Expresswire) -- According to 360 Research Reports, the “Neuropathic Pain Management Market" 2021 by Types (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, ...
- Ask the GP: Chilli pepper cream can be effective in relieving nerve painon February 17, 2021 at 5:08 pm
How miserable for you to be suffering still with nerve pain. But fortunately, it is treatable. Long-term pain following shingles becomes more common with age, with more than 18 per cent of over-70s ...
- Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosison February 17, 2021 at 7:47 am
Lumbar spinal canal stenosis (LSS) or mechanical compression of dorsal root ganglion (DRG) is one of the causes of low back pain and neuropathic pain (NP). Lysophosphatidic acid (LPA) is a potent ...
- Assessment of neuropathic pain after spinal cord injury using quantitative pain drawingson February 16, 2021 at 12:14 pm
Clinimetric cross-sectional cohort study in adults with paraplegic spinal cord injury (SCI) and neuropathic pain (NP). Objective. To assess the reliability of standa ...
- Neuropathic Pain Market Size, Global Industry Share, Growth, Company Profiles, Competitive Landscape, Key Regions Forecast 2021 to 2025on February 16, 2021 at 12:17 am
Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Neuropathic Pain Market” ...
via Bing News
